Access Bio (Korea) Today
| 950130 Stock | KRW 5,280 40.00 0.75% |
PerformanceVery Weak
| Odds Of DistressLow
|
Access Bio is trading at 5280.00 as of the 16th of February 2025, a 0.75 percent decrease since the beginning of the trading day. The stock's open price was 5320.0. Access Bio has less than a 9 % chance of experiencing financial distress in the next few years, but has generated negative returns over the last 90 days. The performance scores are derived for the period starting the 17th of January 2025 and ending today, the 16th of February 2025. Click here to learn more.
Access Bio, Inc. researches, develops, and manufactures in vitro rapid diagnostic tests, biosensors, and molecular diagnostic products. The company has 26.79 M outstanding shares. More on Access Bio
Moving together with Access Stock
Follow Valuation Odds of Bankruptcy
Check how we calculate scores
Access Stock Highlights
Most reasonable investors view market volatility as an opportunity to invest at a favorable price or to sell short against a bearish trend. Access Bio's investment highlights are automatically generated signals that are significant enough to either complement your investing judgment regarding Access Bio or challenge it. These highlights can help you better understand the position you are entering and avoid costly mistakes.
| Business Concentration | Health Care Equipment & Supplies, Healthcare (View all Sectors) |
Access Bio (950130) is traded on KOSDAQ in Korea and employs 69 people. The company currently falls under 'Mega-Cap' category with a current market capitalization of 292.03 B. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Access Bio's market, we take the total number of its shares issued and multiply it by Access Bio's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities. Access Bio operates under Healthcare sector and is part of Health Care Equipment & Supplies industry. The entity has 26.79 M outstanding shares.
Access Bio has accumulated about 167.93 M in cash with 137.9 M of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 828.78.
Check Access Bio Probability Of Bankruptcy
Ownership AllocationAccess Bio holds a total of 26.79 Million outstanding shares. Access Bio retains significant amount of outstanding shares owned by insiders. An insider is usually defined as a CEO, other corporate executive, director, or institutional investor who own at least 10% of the company's outstanding shares. Since such a large part of the company is owned by insiders, it is advisable to analyze if each of these insiders have been buying or selling the stock in recent months. Please note that no matter how many assets the company secures, if the real value of the firm is less than the current market value, you may not be able to make money on it.
Check Access Ownership Details
Access Bio Risk Profiles
Although Access Bio's alpha and beta are two of the key measurements used to evaluate Access Bio's performance over the market, the standard measures of volatility play an important role as well.
| Mean Deviation | 2.5 | |||
| Standard Deviation | 3.88 | |||
| Variance | 15.05 | |||
| Risk Adjusted Performance | (0.02) |
Access Stock Against Markets
Be your own money manager
Our tools can tell you how much better you can do entering a position in Access Bio without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.Did you try this?
Run Portfolio Suggestion Now
Portfolio SuggestionGet suggestions outside of your existing asset allocation including your own model portfolios |
| All Next | Launch Module |
Access Bio Corporate Management
Elected by the shareholders, the Access Bio's board of directors comprises two types of representatives: Access Bio inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Access. The board's role is to monitor Access Bio's management team and ensure that shareholders' interests are well served. Access Bio's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Access Bio's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Andrew Gorman | B Board | Profile | |
| Terry Kim | Chief Africa | Profile | |
| Philip CPA | Treasurer Board | Profile | |
| John Kim | Managing Partner | Profile | |
| N MD | Clinical Board | Profile | |
| YoungHo Choi | CEO Pres | Profile | |
| Janet Strong | DODG Board | Profile |
Other Information on Investing in Access Stock
Access Bio financial ratios help investors to determine whether Access Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Access with respect to the benefits of owning Access Bio security.